Table 2.

Estimated SIRs and CIs for pancreatic cancer by class of family from the BCFR

BRCA1BRCA23 (BRCAX)4 (BRCAX)
ClassObsExpSIR (95% CI)ObsExpSIR (95% CI)ObsExpSIR (95% CI)ObsExpSIR (95% CI)
Overall6741.81.60 (1.26–2.04)6228.22.20 (1.71–2.82)8262.61.31 (1.06–1.63)2061581.30 (1.13–1.49)
Men3222.31.43 (1.01–2.03)3514.72.38 (1.71–3.31)4031.21.28 (0.94–1.75)11277.61.44 (1.20–1.74)
Women3519.41.80 (1.29–2.51)2713.52.00 (1.37–2.91)4231.41.34 (0.99–1.81)9480.81.16 (0.95–1.42)
≤50 y122.564.68 (2.66–8.24)81.674.77 (2.39–9.54)93.992.26 (1.17–4.34)239.922.32 (1.54–3.49)
>50 y5539.21.40 (1.08–1.83)5426.62.03 (1.56–2.66)7358.61.25 (0.99–1.57)1831481.23 (1.07–1.42)
FDRs135.912.20 (1.28–3.79)165.422.95 (1.81–4.81)2219.01.16 (0.76–1.76)8367.01.24 (1.00–1.54)
Population-based168.151.96 (1.20–3.20)166.712.38 (1.46–3.89)3029.41.02 (0.71–1.46)11295.11.18 (0.98–1.42)
Clinic-based5133.61.52 (1.15–2.00)4621.52.14 (1.60–2.85)5233.11.57 (1.20–2.06)9463.21.49 (1.21–1.82)
≤2 BC2814.02.00 (1.38–2.89)349.843.45 (2.47–4.83)
≥3 BC3927.71.41 (1.03–1.92)2818.41.52 (1.05–2.21)

Abbreviations: BC, breast cancer; Exp, expected number of cases; Obs, observed number of cases.